Lindsey Roeker, MD, spoke about identifying the correct population of patients with chronic lymphocytic leukemia who will benefit from umbralisib and ublituximab plus ibrutinib.
At the 2021 American Society of Hematology Annual Meeting, CancerNetwork® spoke with Lindsey Roeker, MD, a hematologic oncologist at Memorial Sloan Kettering Cancer Center in New York, about why umbralisib (Ukoniq) and ublituximab (TGTX-1101) plus ibrutinib (Imbruvica) is a potentially important regimen and how it can help improve treatment for those with chronic lymphocytic leukemia.
I think that the combination of ibrutinib, umbralisib, and ublituximab is a really promising one. This might allow us a step-up approach that identifies patients who are in need of the combination therapy after exposure to ibrutinib monotherapy. We’re still trying to figure out who the ideal patient is for the combination approach [with the] understanding that there is added toxicity with the drugs together, but there’s also added efficacy. How do we optimally select those patients? This is a novel treatment design that allows us to really identify a patient population that might benefit most.
Roeker L, Leslie L, Soumerai J, et al. A phase 2 study evaluating the addition of ublituximab and umbralisib (U2) to ibrutinib in patients with chronic lymphocytic leukemia (CLL): A minimal residual disease (MRD)- driven, time-limited approach. Presented at the 2021 American Society of Hematology Annual Meeting. December 11-14, 2021. Abstract 395. https://bit.ly/3sKm471